Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included a new brief submitted to the Supreme Court in which Amgen Inc. argued the Zarxio biosimilar lawsuit is a "poor vehicle" for interpreting the Biologics Price Competition and Innovation Act, and therefore, Sandoz Inc.'s petition to hear the case should be denied; another eye-opener involving Valeant Pharmaceutical International Inc.'s pricing practices, which this time involved Seconal, a drug used off-label in physician-assisted suicides; a decision by the Patent Trial and Appeal Board of the US Patent & Trademark Office to institute an inter partes review petition from hedge fund manager Kyle Bass challenging a patent held by Biogen Inc. on its 480mg dose of its multiple sclerosis drug Tecfidera (dimethyl fumarate); and the FDA's approval of Pine Brook, NJ-based Elusys Therapeutics Inc.'s Anthim (obiltoxaximab) in combination with appropriate antibacterial drugs to treat inhalational anthrax and prevent the disease when alternative therapies are not available or are not appropriate; plus other Washington news.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064834

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel